TG Therapeutics (TGTX) Shares Up 1.8%

TG Therapeutics Inc (NASDAQ:TGTX) shares shot up 1.8% during trading on Thursday . The company traded as high as $14.15 and last traded at $14.25. 296,055 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,550,473 shares. The stock had previously closed at $14.00.

A number of brokerages have recently commented on TGTX. B. Riley reiterated a “buy” rating and issued a $27.00 price target (up from $21.50) on shares of TG Therapeutics in a research note on Friday, March 9th. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, March 6th. ValuEngine upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Zacks Investment Research upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 16th. Finally, HC Wainwright restated a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $24.60.

The firm has a market cap of $993.87, a price-to-earnings ratio of -7.56 and a beta of 1.20.



TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.46). The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 145.58% and a negative net margin of 77,945.40%. equities analysts anticipate that TG Therapeutics Inc will post -1.68 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. Senzar Asset Management LLC increased its holdings in TG Therapeutics by 56.9% in the fourth quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock valued at $11,112,000 after purchasing an additional 491,678 shares during the period. University of Notre Dame DU Lac acquired a new stake in TG Therapeutics during the 4th quarter worth about $2,483,000. Goldman Sachs Group Inc. grew its holdings in TG Therapeutics by 1,335.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 311,793 shares of the biopharmaceutical company’s stock worth $2,557,000 after acquiring an additional 290,066 shares during the period. Kennedy Capital Management Inc. grew its holdings in TG Therapeutics by 39.0% during the 4th quarter. Kennedy Capital Management Inc. now owns 585,439 shares of the biopharmaceutical company’s stock worth $4,801,000 after acquiring an additional 164,210 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in TG Therapeutics by 176.8% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock worth $2,886,000 after acquiring an additional 155,535 shares during the period. Institutional investors and hedge funds own 47.33% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “TG Therapeutics (TGTX) Shares Up 1.8%” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/12/tg-therapeutics-tgtx-shares-up-1-8.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply